Why Farbe Firma is the Top Manufacturer of Tranexamic Acid Injection
- Maulik Sudani
- May 27
- 6 min read
Last Updated: May 27, 2026
TL;DR: Tranexamic Acid Injection — a sterile, ready-to-use parenteral antifibrinolytic supplied most commonly as 100 mg/mL in 5 mL ampoules (500 mg) and 10 mL ampoules (1,000 mg) — is the first-line agent for the control and prevention of haemorrhage in obstetric, surgical, trauma, dental, urological and oncology settings. By competitively inhibiting plasminogen activation it stabilises the fibrin clot, reduces blood loss and demonstrably lowers all-cause mortality when given within 3 hours in major trauma and post-partum haemorrhage. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Tranexamic Acid Injection at our Gujarat, India facility and supplies it to hospital tenders, trauma and obstetric programmes, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Antifibrinolytic — Tranexamic Acid Injection is a synthetic lysine analogue that competitively blocks the lysine-binding sites on plasminogen, preventing its conversion to plasmin and the subsequent breakdown of fibrin. The parenteral route gives reliable plasma levels within minutes and is the standard of care for post-partum haemorrhage, major trauma haemorrhage (CRASH-2/WOMAN evidence), cardiac and orthopaedic surgery, hyperfibrinolysis, and high-risk dental extractions in patients on anticoagulation.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule and vial filling lines, terminal sterilisation cycles validated for the heat-stable Tranexamic Acid molecule, and full container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, drug master files and CEP-style documentation, supporting registrations across regulated and emerging markets including obstetric-haemorrhage tenders for ministry-of-health programmes.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Tranexamic Acid Injection Demands a Premium Manufacturer
Tranexamic Acid Injection sits at the very front line of bleeding management in modern hospital medicine. When a post-partum haemorrhage refuses to settle with uterotonics, when a polytrauma patient arrives in haemorrhagic shock, when a cardiac or major orthopaedic operation crosses its predicted blood-loss threshold, or when a haemophilia patient needs cover for a dental extraction, intravenous tranexamic acid is the agent that buys time and saves lives. The CRASH-2 and WOMAN trials translated that bedside experience into hard evidence: a one-gram intravenous dose given within 3 hours of trauma or post-partum bleeding reduces death due to bleeding without increasing thrombotic events. Because the drug is given to actively bleeding, physiologically unstable patients — often in life-threatening windows — the consequences of a sub-potent, contaminated or precipitated ampoule are immediate and irreversible.
That clinical context places real demands on the manufacturer. Tranexamic acid is a small, water-soluble, heat-stable lysine analogue, but it must be delivered as a crystal-clear, particulate-free solution at a tightly controlled pH around 6.5 to 8.0, reliably sterile and endotoxin-free, and stable across the long, hot supply chains of the emerging-market hospital systems where Farbe Firma's customers operate. It must also be compatible with the co-administered fluids, oxytocin infusions, blood products and central-line setups that surround a bleeding patient. Choosing a Tranexamic Acid Injection manufacturer that treats particulate-free filling, assay precision and validated stability as core engineering disciplines is what keeps obstetric and trauma wards safe.
What Sets a World-Class Tranexamic Acid Injection Manufacturer Apart
A world-class manufacturer of Tranexamic Acid Injection invests in three areas that weaker suppliers underfund: precision assay and pH control, a sterility and particulate programme built for a small-volume parenteral that meets a bleeding patient, and CTD-grade stability evidence that withstands review by stringent regulators. It starts with the active pharmaceutical ingredient — pharmacopoeial-grade tranexamic acid sourced from qualified, audited API manufacturers, with full impurity profiling and certificates of analysis cross-checked by the receiving laboratory before any material enters production.
Formulation, filling and packaging then have to protect the molecule end to end. The solution pH is tightly controlled, in-process assay confirms label strength, and filling is performed under ISO Class 5 air in clear glass ampoules with rigorous visible and sub-visible particulate limits. Terminal sterilisation is validated specifically for the heat-stable Tranexamic Acid molecule with load mapping for each container format, and container-closure integrity is verified. Stability is tracked under ICH Q1A long-term and accelerated conditions across all label strengths and pack sizes. World-class plants also maintain a deep batch-record discipline so that, in the rare event of a customer complaint or a recall query from a national regulator, every single unit is traceable to its API lot, its filling-line shift and its release decision.
Quality Systems Behind Every Tranexamic Acid Injection
Every Farbe Firma Tranexamic Acid Injection batch is released only after a full stack of quality checks: HPLC assay against USP, BP, IP or EP reference standards, related-substance and degradation-product profiling, pH, osmolality, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-volume verification appropriate to the ampoule or vial format. Certificates of analysis are issued with full traceability back to API lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping for each container format, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — so we can assure customers that the Tranexamic Acid Injection they buy today will still meet specification when it reaches the patient months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Tranexamic Acid Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across critical-care, obstetric, trauma, anti-infective and supportive-care categories. For Tranexamic Acid Injection specifically, we supply 100 mg/mL in 5 mL ampoules (500 mg) and 10 mL ampoules (1,000 mg), with country-specific strengths, container formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Tranexamic Acid Injection at tender scale — and ministry-of-health post-partum-haemorrhage and trauma procurements are almost always high-volume and time-critical — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, particulate control, sterilisation, container-closure and stability choices in real detail. For a drug given to actively bleeding patients in life-saving windows, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Tranexamic Acid Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Tranexamic Acid Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule and vial filling lines, qualified water-for-injection systems and validated environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Tranexamic Acid Injection do you supply?
Our standard presentations are 100 mg/mL in 5 mL ampoules (500 mg) and 10 mL ampoules (1,000 mg). Clear glass ampoules, custom fill volumes, vial presentations and country-specific pack configurations are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Tranexamic Acid Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability packages, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia, including obstetric-haemorrhage tender programmes for ministry-of-health buyers.
How does Farbe Firma assure the potency and sterility of Tranexamic Acid Injection?
We run HPLC assay and related-substances testing on every batch, control pH within a tightly validated window, package in pharmaceutical-grade glass ampoules, and qualify each batch against ICH Q1A long-term and accelerated stability protocols. Endotoxin by LAL, sterility by membrane filtration and container-closure integrity are confirmed on every batch before release.
What is the minimum order quantity for Tranexamic Acid Injection contract manufacturing?
MOQs vary by strength, container format, label complexity and dossier requirements. For both 500 mg and 1,000 mg ampoule presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments